

# **Prevas**

### Positioned for improved conditions

- · Seasonally weak quarter
- We cut '25e-'27e adj. EBITA by 2%
- Trading ~20% below current peers on '25e EV/EBITA

#### Q3: Built for the long term

Prevas will release its Q3'25 report on 24 October. We expect sales of SEK 351m, flat y-o-y growth, reflecting seasonal softness, as the holiday period typically weighs on activity across the consulting sector. We estimate organic growth at -3%, primarily due to fewer billable days and continued market slowdowns. We anticipate adj. EBITA of SEK 23m, implying an adj. EBITA margin of 7%. We continue to see defence and energy segments as solid growth areas. In Finland, market conditions appear to be gradually improving, supported by a solid order book and the integration of Enmac. The medtech acquisition in southern Sweden (OIM) was consolidated at the end of Q3, and we expect a minor positive impact on the result.

#### Minor adjustments to estimates

We make minor changes to our estimates and cut '25e-'27e adj. EBITA by 2%, which reflects continued softness in market conditions. That said, we view this as a cyclical downturn rather than structural. When consultants are between projects, costs persist while revenue lags. We expect this effect to gradually normalise as demand stabilises and project onboarding accelerates in H1'26e. Furthermore, we believe that Finland (as well as core segments like defence and energy) will continue to strengthen Prevas' position.

### **Trading below peers**

Based on our revised estimates, Prevas is trading at 10-5x '25e-'27e EV/ EBITA, which is ~20% below current peer multiples. Moreover, Prevas is trading ~15% below its historical EV/EBITA multiple. In our view, current earnings are cyclically depressed, and we do not believe the current margin profile reflects Prevas' long-term earnings capacity. As operational efficiencies begin to materialise and utilisation recovers, we see room for earnings expansion.

#### Reason: Preview of results

#### Commissioned research

#### Not rated

#### **Services**

Estimate changes (%)

	2025e	2026e	2027e
Sales	-0.4	-2.3	-2.1
EBIT	-2.4	-2.3	-2.3
EPS	-2.7	-2.3	-2.3
Source: ABG Sundal Collier			

10/10/2025

65.80

#### PREV.B-SE/PREVb SS

Share price (SEK)

MCap (SEKm)	848
MCap (EURm)	77
No. of shares (m)	12.5
Free float (%)	52.5
Av. daily volume (k)	77

Next event Q3 Report 24 October 2025

#### **Performance**



Analyst: dafina.shehu@abgsc.se, +46 8 566 286 59

SEKm	2023	2024	2025e	2026e	2027e
Sales	1,483	1,587	1,620	1,683	1,807
EBITDA	205	175	162	199	242
					13.4
EBITDA margin (%)	13.8	11.0	10.0	11.8	
EBIT adj.	165	138	107	148	188
EBIT adj. margin (%)	11.1	8.7	6.6	8.8	10.4
Pretax profit	160	120	94	139	179
EPS	9.47	7.20	5.79	8.59	11.03
Sales growth (%)	12.0	7.0	2.1	3.9	7.4
EPS growth (%)	-0.7	-24.0	-19.6	48.4	28.4


Source: ABG Sundal Collier, Company Data

	2025e	2026e	2027e
P/E (x)	11.4	7.7	6.0
P/E adj. (x)	9.7	6.9	5.5
P/BVPS (x)	1.30	1.19	1.07
EV/EBITDA (x)	7.1	5.5	4.2
EV/EBIT adj. (x)	10.9	7.4	5.4
EV/sales (x)	0.72	0.65	0.56
ROE adj. (%)	13.8	18.3	20.9
Dividend yield (%)	5.5	7.2	8.4
FCF yield (%)	13.2	17.3	20.6
Le. adj. FCF yld. (%)	9.3	13.3	16.1
Net IB debt/EBITDA (x)	1.6	0.9	0.5
Le. adj. ND/EBITDA (x)	0.8	0.2	-0.2

### Company description

Prevas is a technological consultancy firm specialised in products and production solutions, working within areas such as digitalisation, sustainability, connectivity, and life science. Prevas has diverse end markets: the most significant are life science, engineering, energy and defence. The company's clients are global, but most of its personnel are located in Sweden. Prevas' strategy is to provide critical value to its customers and therefore to sustain long client relationships.

#### Revenue (SEKm) and y-o-y growth (%)



Source: ABG Sundal Collier, Company data

#### Adj. EBITA (SEKm) and adj. EBITA margin (%)



Source: ABG Sundal Collier, Company data

#### Free cash flow (SEKm)




Source: ABG Sundal Collier, Company data

#### **Risks**

Prevas is largely dependent on investment activities in its sectors (such as energy, engineering and life science), which can experience drawdowns in recessions. The company also needs to attract and retain qualified employees to sustain its operations, and there is a growing shortage of engineers in Sweden. That could lead to higher salaries and difficulties employing and retaining staff, as prospective employees have greater bargaining power.

#### Quarterly organic growth y-o-y (%)



Source: ABG Sundal Collier, Company data

#### EPS, DPS and payout ratio



Source: ABG Sundal Collier, Company data

### Net debt (SEKm) and net debt/EBITDA lease adj.



Source: ABG Sundal Collier, Company data

### **Technical consulting market overview**

The following graphs are based on the most recent data from the National Institute of Economic Research, a Swedish government agency reporting to the Ministry of Finance. Q3'25 market data showed lower demand and hourly prices for technical consultants, likely reflecting project delays and increased competition in a market with continued excess consultant capacity.

#### Demand outcome vs. expectations



Source: National Institute of Economic Research (Swe: Konjunkturinstitutet)

#### Hourly prices outcome vs. expectations



Source: National Institute of Economic Research (Swe: Konjunkturinstitutet)

## Historical EV/EBITA f12m multiple

Prevas is trading ~15% below its historical EV/EBITA multiple.

#### Prevas vs. historical multiple. EV/EBITA f12m



Source: ABG Sundal Collier, FactSet

# **Peers**


Prevas is trading ~20-40% below its peers for '25e-'27e EV/EBITA.

#### Peer table

Company	mCap (SEKm)	S	Sales growth (%)			EV/EBITA			P/E			
		2025e	2026e	2027e	2025e	2026e	2027e	2025e	2026e	2027e		
Etteplan	2,810	-1%	4%	4%	12x	10x	8x	15x	13x	11x		
Multiconsult	4,472	4%	9%	6%	13x	11x	9x	16x	13x	11x		
SWECO B	57,021	3%	7%	5%	19x	17x	15x	25x	22x	20x		
AFRY B	18,890	-3%	4%	6%	14x	11x	9x	16x	12x	10x		
Rejlers AB B	4,231	6%	7%	5%	12x	10x	8x	15x	13x	11x		
Knowit	2,851	-7%	3%	5%	12x	9x	6x	40x	16x	10x		
Average	15,046	0%	6%	5%	14x	11x	9x	21x	15x	12x		
Median	4,351	1%	5%	5%	12x	10x	9x	16x	13x	11x		
Prevas (ABGSCe)	848	2%	4%	7%	10x	7x	5x	11x	8x	6x		
Premium/discount	•	·	·	·	-20%	-34%	-41%	-28%	-41%	-46%		

Source: ABG Sundal Collier, FactSet

### Prevas vs. peers



Source: ABG Sundal Collier, FactSet

# Estimate changes and overview of figures

## **Estimate changes**

		Old forecas	t		New forecas	it			
SEKm	2025e	2026e	2027e	2025e	2026e	2027e	2025e	2026e	2027e
Net sales	1,626	1,722	1,845	1,620	1,683	1,807	0%	-2%	-2%
Other external costs	<del>-443</del>	<del>-</del> 470	<del>-</del> 498	<del>-</del> 439	<del>-</del> 460	<del>-4</del> 88	-1%	-2%	-2%
Personnel costs	-1,018	-1,048	-1,100	-1,019	-1,024	-1,078	0%	-2%	-2%
Adj. EBITA	121	163	204	119	160	200	-2%	-2%	-2%
EBIT	108	151	192	105	148	188	-2%	-2%	-2%
Net profit	77	113	145	75	111	142	-3%	-2%	-2%

Source: ABG Sundal Collier, Company data

### Quarterly overview (SEKm)

Quarterly overview (SEKm)	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25e	Q4'25e
Net sales	407	396	352	432	431	409	351	430
Other external costs	-121	-116	-104	<del>-</del> 122	-116	-108	<b>-</b> 97	-118
Personnel costs	-231	-236	-215	-266	-268	-270	-220	-260
EBITA	46	34	21	32	35	20	23	39
Adj. EBITA	53	36	26	33	35	27	23	39
EBIT	44	32	18	29	32	17	20	36
Net profit	33	26	10	23	23	10	15	27
EPS	2.54	2.01	0.75	1.81	1.75	0.73	1.13	2.11
Total sales growth y-o-y	3%	5%	13%	8%	6%	3%	0%	-1%
Organic growth y-o-y	1%	3%	-1%	-6%	-6%	-9%	-3%	-3%
EBITA margin	11%	9%	6%	7%	8%	5%	7%	9%
Adj. EBITA margin	13%	9%	7%	8%	8%	7%	7%	9%
EBIT margin	11%	8%	5%	7%	7%	4%	6%	8%

Source: ABG Sundal Collier, Company data

#### **Annual overview**

Annual overview (SEKm)	2020	2021	2022	2023	2024	2025e	2026e	2027e
Net sales	772	1,187	1,324	1,483	1,587	1,620	1,683	1,807
y-o-y growth (%)	-3.1%	53.8%	11.6%	12.0%	7.0%	2.1%	3.9%	7.4%
Organic growth (%)	-3.1%	11.6%	8.4%	5.7%	-0.8%	-5.1%	2.8%	7.4%
M&A (%)	0.0%	42.2%	3.2%	6.2%	7.8%	7.3%	1.1%	0.0%
Other external costs	<b>-</b> 196	<b>-</b> 312	-354	-427	-464	-439	-460	<del>-</del> 488
Personnel costs	<del>-</del> 483	-715	-777	-851	-949	-1,019	-1,024	-1,078
adj. EBITDA	92	159	193	207	190	164	199	242
Total D&A	<del>-</del> 27	-36	-34	<del>-4</del> 2	<b>-</b> 52	<b>-</b> 57	-51	-54
adj. EBITA	66	127	164	172	148	119	160	200
adj. EBITA-margin (%)	8.5%	10.7%	12.4%	11.6%	9.3%	7.3%	9.5%	11.1%
EBIT	66	133	159	162	123	105	148	188
EPS after dilution	4.49	8.21	9.54	9.47	7.20	5.79	8.59	11.03
EPS after dilution growth y-o-y	40.2%	82.6%	16.3%	-0.7%	-24.0%	-19.6%	48.4%	28.4%
Payout ratio (%)	0.0%	24.4%	47.2%	50.1%	66.0%	62.0%	55.0%	50.0%

Source: ABG Sundal Collier, Company data

Income Statement (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Sales	771	796	772	1,187	1,324	1,483	1,587	1,620	1,683	1,807
COGS	0	0	0	0	0	0	0	0	0	0
Gross profit	771	796	772	1,187	1,324	1,483	1,587	1,620	1,683	1,807
Other operating items	-755	-721	-679	-1,018	-1,131	-1,278	-1,412	-1,457	-1,484	-1,565
EBITDA	16	75	92	169	193	205	175	162	199	242
Depreciation and amortisation	-7	-28	-27	-32	-28	-35	-42	-45	-39	-42
of which leasing depreciation	0	-24	-23	-29	-25	-31	-37	-40	-34	-36
EBITA	10	47	66	137	164	169	132	117	160	200
EO Items	0	0	0	10	0	-2	-16	-1	0	0
Impairment and PPA amortisation	0	0	0	-4	-5	-7	-10	-12	-12	-12
EBIT	10	47	66	133	159	162	123	105	148	188
Net financial items	-2	-5	-6	-7	-5	-2	-2	-11	-8	-9
Pretax profit	7	42	60	126	154	160	120	94	139	179
Tax	-2	-10	-15	-23	-32	-39	-28	-20	-29	-37
Net profit	6	32	45	103	122	121	92	75	111	142
Minority interest	0	0 0	0 0	0 0	0 0	3 0	1	2 0	2 0	3
Net profit to abarahaldara	6	32				124		<b>76</b>		145
Net profit to shareholders	0.56	3.21	<b>45</b> 4.49	<b>103</b> 8.21	<b>122</b> 9.54	9.47	<b>93</b> 7.20	5.79	<b>113</b> 8.59	11.03
EPS EPS adj.	0.56	3.21	4.49 4.47	7.68	9.54	10.24	8.79	6.75	9.51	12.00
·	0.50	0	0	8	0	-2	-12	-1	9.51	0
Total extraordinary items after tax	0	-24	-23	-29	-25	-2 -31	-37	-40	-34	-36
Leasing payments  Tax rate (%)	22.9	23.5	-23 24.4	-23 18.3	20.8	24.4	23.3	20.9	20.6	20.6
Gross margin (%)	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
EBITDA margin (%)	2.1	9.4	11.9	14.2	14.6	13.8	11.0	10.0	11.8	13.4
EBITA margin (%)	1.2	5.9	8.5	11.5	12.4	11.4	8.3	7.2	9.5	11.1
EBIT margin (%)	1.2	5.9	8.5	11.2	12.0	11.0	7.7	6.5	8.8	10.4
Pre-tax margin (%)	0.9	5.3	7.7	10.6	11.6	10.8	7.6	5.8	8.3	9.9
Net margin (%)	0.7	4.1	5.9	8.7	9.2	8.2	5.8	4.6	6.6	7.9
Growth Rates y-o-y	-	-	-				-		-	
Sales growth (%)	4.9	3.3	-3.1	53.8	11.6	12.0	7.0	2.1	3.9	7.4
EBITDA growth (%)	-36.7	361.0	22.5	83.1	14.3	6.1	-14.7	-6.9	22.5	21.6
EBITA growth (%)	-41.2	395.0	39.3	108.8	20.2	3.0	-21.9	-11.5	36.5	25.1
EBIT growth (%)	-41.2	nm	39.3	nm	19.5	2.0	-24.5	-14.3	40.7	27.2
Net profit growth (%)	-51.1	475.3	39.6	127.3	18.6	-0.8	-23.7	-19.2	48.4	28.4
EPS growth (%)	-51.1	nm	40.2	82.6	16.3	-0.7	-24.0	-19.6	48.4	28.4
Profitability	-	-	-	-	-	-	-	-	-	-
ROE (%)	3.7	19.0	21.7	29.4	24.0	21.5	14.9	11.8	16.6	19.3
ROE adj. (%)	3.7	19.0	21.7	28.2	25.0	23.0	18.4	13.8	18.3	20.9
ROCE (%)	4.4	20.1	24.8	31.4	25.6	23.5	14.0	10.3	14.4	17.1
ROCE adj. (%)	4.4	20.1	24.8	30.0	26.5	24.9	16.9	11.6	15.5	18.2
ROIC (%)	3.4	15.5	22.4	34.7	25.1	21.6	12.7	9.4	13.2	16.5
ROIC adj. (%)	3.4	15.5	22.4	32.3	25.1	21.9	14.2	9.6	13.2	16.5
Adj. earnings numbers	-	-	-	-	-	-	-	-	-	-
EBITDA adj.	16	75	92	159	193	207	190	164	199	242
EBITDA adj. margin (%)	2.1	9.4	11.9	13.4	14.6	14.0	12.0	10.1	11.8	13.4
EBITDA lease adj.	16	52	69	131	168	176	153	124	165	206
EBITDA lease adj. margin (%)	2.1	6.5	8.9	11.0	12.7	11.8	9.7	7.6	9.8	11.4
EBITA adj.	10	47	66	127	164	172	148	119	160	200
EBITA adj. margin (%)	1.2	5.9	8.5	10.7	12.4	11.6	9.3	7.3	9.5	11.1
EBIT adj.	10	47	66	124	159	165	138	107	148	188
EBIT adj. margin (%)	1.2	5.9	8.5	10.4	12.0	11.1	8.7	6.6	8.8	10.4
Pretax profit Adj.	7	42	60 45	120	159	169	146	108	151	191
Net profit Adj.	6	32	45 45	99	127	130	114	88	123	154
Net profit to shareholders adj.	6 <i>0.7</i>	32 <i>4.1</i>	45 5.9	99 8.3	127 9.6	133 8.8	115 7.2	89 5. <i>4</i>	125 7.3	157 8.5
Net adj. margin (%)		7.1	J.9	0.3	9.0	0.0	1.2	J.4	7.3	0.0
Source: ABG Sundal Collier, Company										
Cash Flow (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
EBITDA	16	75	92	169	193	205	175	162	199	242
Net financial items	-2	-5	-6	-7	-5	-2	-2	-11	-8	-9
Paid tax	-2	-4	-6	-23	-36	-44	-53	-34	-29	-37
Non-cash items	1	-7	-14	-37	2	-10	-6	1	0	0
Cash flow before change in WC	13	60	67	101	154	148	113	119	162	196
Change in working capital	5	-1	51	-23	-51	16	24	1	-6	-12

Cash Flow (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Operating cash flow	18	59	118	79	103	164	137	120	156	184
Capex tangible fixed assets	-2	-2	-2	-4	-5	-4	-7	-5	-8	-9
Capex intangible fixed assets	-1	-1	0	-1	0	0	-2	-3	-1	-1
Acquisitions and Disposals	-1	0	0	-53	-45	-11	-191	-0	0	0
Free cash flow	15	56	116	21	53	149	-63	112	147	175
Dividend paid	-0	-2	0	-25	-45	-58	-63	-63	-46	-61
Share issues and buybacks	0	0	0	1	0	-7	1	0	0	0
Leasing liability amortisation	0	-24	-18	-27	-26	-31	-35	-33	-34	-38
Other non-cash items	-1	-40	3	-13	-34	6	-212	28	1	3
Balance Sheet (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Goodwill	136	137	136	325	373	406	670	662	662	662
Other intangible assets	4	3	1	27	38	32	48	37	25	13
Tangible fixed assets	4	4	4	7	9	10	15	16	19	23
Right-of-use asset	12	52	44	37	60	54	158	135	134	133
Total other fixed assets	4	2	2	2	5	5	38	36	36	36
Fixed assets	161	198	187	397	485	507	929	885	876	867
Inventories	1	1	0	0	2	13	3	4	4	4
Receivables	161	147	131	218	285	290	303	470	488	525
Other current assets	48	53	53	86	142	138	157	0	0	0
Cash and liquid assets	1	1	84	122	83	112	44	35	101	177
Total assets	371 454	399	454	824	996	1,060	1,437	1,394	1,470	1,573
Shareholders equity	154	187	230	469	548	605	647	651	713	791
Minority	3 <b>157</b>	2 <b>189</b>	1 <b>231</b>	2 <b>472</b>	19 <b>567</b>	35 <b>640</b>	57 <b>703</b>	55 <b>706</b>	58 <b>771</b>	61 <b>852</b>
Total equity	0	2	0	<b>472</b> 45	23	2	133	89	89	89
Long-term debt Pension debt	0	0	0	45 0	0	0	0	0	0	0
Convertible debt	0	0	0	0	0	0	0	0	0	0
Leasing liability	12	50	43	37	56	50	156	154	153	150
Total other long-term liabilities	7	8	13	32	49	46	84	80	80	80
Short-term debt	44	14	0	23	22	23	50	48	48	48
Accounts payable	44	29	38	51	51	81	80	82	85	91
Other current liabilities	107	108	131	164	228	219	230	235	244	262
Total liabilities and equity	371	399	454	824	996	1,060	1,437	1,394	1,470	1,573
Net IB debt	55	65	-41	-18	18	-37	295	256	189	110
Net IB debt excl. pension debt	55	65	-41	-18	18	-37	295	256	189	110
Net IB debt excl. leasing	43	15	-84	-54	-38	-88	139	102	36	-40
Capital employed	213	254	274	576	667	715	1,042	997	1,061	1,139
Capital invested	212	254	190	454	585	602	998	962	959	962
Working capital	59	64	15	89	149	141	153	157	163	175
EV breakdown	_	-	-	-	-	-	-	-	-	_
Market cap. diluted (m)	665	665	665	838	840	840	844	848	848	848
Net IB debt adj.	55	65	-41	-18	18	-37	295	256	189	110
Market value of minority	3	2	1	2	19	35	57	55	58	61
Reversal of shares and	0	0	0	0	0	0	0	0	0	0
participations										
Reversal of conv. debt assumed	-	-	-	-	-	-	-	-	-	-
equity <b>EV</b>	723	731	625	822	877	838	1,195	1,159	1,094	1,019
Total assets turnover (%)	209.6	206.7	180.8	185.7	145.5	144.2	127.1	114.5	117.5	118.8
Working capital/sales (%)	8.1	7.7	5.1	4.4	9.0	9.8	9.3	9.6	9.5	9.3
Financial risk and debt service	-		-	-	-		0.0		-	- 0.0
Net debt/equity (%)	35.4	34.5	-17.8	-3.8	3.2	-5.8	42.0	36.3	24.5	12.9
Net debt/equity (70)	8.3	9.8	-6.2	-2.1	2.1	-4.4	35.0	30.2	22.2	13.0
Equity ratio (%)	42.2	47.2	50.8	57.2	56.9	60.3	48.9	50.7	52.4	54.2
Net IB debt adj. / equity (%)	35.4	34.5	-17.8	-3.8	3.2	-5.8	42.0	36.3	24.5	12.9
Current ratio	1.08	1.34	1.59	1.79	1.69	1.72	1.41	1.39	1.57	1.76
EBITDA/net interest	7.4	16.0	16.1	22.9	36.4	85.4	75.1	15.1	23.6	26.8
Net IB debt/EBITDA (x)	3.4	0.9	-0.4	-0.1	0.1	-0.2	1.7	1.6	0.9	0.5
Net IB debt/EBITDA lease adj. (x)	2.7	0.3	-1.2	-0.4	-0.2	-0.5	0.9	0.8	0.2	-0.2
Interest coverage	4.3	10.0	11.4	18.6	31.1	70.7	56.9	10.9	19.0	22.1
Source: ABG Sundal Collier, Company L	Data						I_			
		2040	2020	2024	2022	2022	2024	2025-	2020-	2027-
Share Data (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Actual shares outstanding	10 10	10 10	10 10	13 13	13 13	13 13	13	13 13	13	13 13
Actual shares outstanding (avg)	10	10	10	13	13	13	13	13	13	13

## Prevas

Share Data (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
All additional shares	0	0	0	3	0	0	0	0	0	0
Issue month	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Assumed dil. of shares from conv.	0	0	0	0	0	0	0	0	0	0
As. dil. of shares from conv. (avg)	0	0	0	0	0	0	0	0	0	0
Conv. debt not assumed as equity	0	0	0	0	0	0	0	0	0	0
No. of warrants	0	0	0	0	0	0	0	0	0	0
Market value per warrant	0	0	0	0	0	0	0	0	0	0
Dilution from warrants	0	0	0	0	0	0	0	0	0	0
Issue factor	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
Actual dividend per share	0.00	0.00	0.00	2.00	4.50	4.75	4.75	3.59	4.72	5.51
Reported earnings per share	0.56	3.21	4.49	8.21	9.54	9.47	7.20	5.79	8.59	11.03

Source: ABG Sundal Collier, Company Data

Valuation and Ratios (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Shares outstanding adj.	10	10	10	13	13	13	13	13	13	13
Diluted shares adj.	10	10	10	13	13	13	13	13	13	13
EPS	0.56	3.21	4.49	8.21	9.54	9.47	7.20	5.79	8.59	11.03
Dividend per share	0.00	0.00	0.00	2.00	4.50	4.75	4.75	3.59	4.72	5.51
EPS adj.	0.56	3.21	4.47	7.68	9.87	10.24	8.79	6.75	9.51	12.00
BVPS	15.22	18.49	22.75	36.86	42.88	47.34	50.43	50.50	55.32	61.39
BVPS adj.	1.30	4.65	9.15	9.22	10.76	13.06	-5.59	-3.71	2.02	9.00
Net IB debt/share	5.49	6.43	-4.07	-1.40	1.40	-2.92	23.02	19.87	14.64	8.54
Share price	65.80	65.80	65.80	65.80	65.80	65.80	65.80	65.80	65.80	65.80
Market cap. (m)	665	665	665	838	840	840	844	848	848	848
Valuation	-	-	-	-	-	-	-	-	-	-
P/E (x)	nm	20.5	14.6	8.0	6.9	6.9	9.1	11.4	7.7	6.0
EV/sales (x)	0.9	0.9	8.0	0.7	0.7	0.6	0.8	0.7	0.7	0.6
EV/EBITDA (x)	44.3	9.7	6.8	4.9	4.5	4.1	6.8	7.1	5.5	4.2
EV/EBITA (x)	76.1	15.5	9.5	6.0	5.3	4.9	9.0	9.9	6.8	5.1
EV/EBIT (x)	76.1	15.5	9.5	6.2	5.5	5.2	9.7	11.0	7.4	5.4
Dividend yield (%)	0.0	0.0	0.0	3.0	6.8	7.2	7.2	5.5	7.2	8.4
FCF yield (%)	2.2	8.4	17.5	2.5	6.3	17.8	-7.4	13.2	17.3	20.6
Le. adj. FCF yld. (%)	2.2	4.8	14.8	-0.7	3.1	14.1	-11.6	9.3	13.3	16.1
P/BVPS (x)	4.32	3.56	2.89	1.79	1.53	1.39	1.30	1.30	1.19	1.07
P/BVPS adj. (x)	38.30	13.28	7.08	5.81	4.80	4.22	-36.00	-77.74	16.56	6.55
P/E adj. (x)	nm	20.5	14.7	8.6	6.7	6.4	7.5	9.7	6.9	5.5
EV/EBITDA adj. (x)	44.3	9.7	6.8	5.2	4.5	4.0	6.3	7.1	5.5	4.2
EV/EBITA adj. (x)	76.1	15.5	9.5	6.5	5.3	4.9	8.1	9.8	6.8	5.1
EV/EBIT adj. (x)	76.1	15.5	9.5	6.7	5.5	5.1	8.6	10.9	7.4	5.4
EV/CE (x)	3.4	2.9	2.3	1.4	1.3	1.2	1.1	1.2	1.0	0.9
Investment ratios	-	-	-	-	-	-	-	-	-	-
Capex/sales (%)	0.4	0.3	0.3	0.4	0.4	0.3	0.5	0.5	0.5	0.5
Capex/depreciation	0.4	0.6	0.6	1.5	1.6	1.1	1.7	1.5	1.6	1.6
Capex tangibles / tangible fixed assets	40.3	52.9	50.4	58.3	57.7	43.1	47.1	33.2	42.6	38.5
Capex intangibles / definite intangibles										
Depreciation on intang / def. intang										
Depreciation on tangibles / tangibles	104.2	64.4	45.8	33.9	30.6	33.3	29.2	30.1	26.0	23.8

Source: ABG Sundal Collier, Company Data

#### **Analyst Certification**

We, ABGSC Services Research and Dafina Shehu, analyst(s) with ABG Sundal Collier ASA, ABG Sundal Collier Denmark, filial af ABG Sundal Collier ASA, Norge, ABG Sundal Collier AB and/or ABG Sundal Collier Limited (hereinafter collectively referred to as "ABG Sundal Collier"), and the author(s) of this report, certify that not withstanding the existence of any such potential conflicts of interests referred to below, the views expressed in this report accurately reflect my/our personal view about the companies and securities covered in this report. I/We further certify that I/We has/have not been, nor am/are or will be, receiving direct or indirect compensation related to the specific recommendations or views contained in this report.

This report is produced by ABG Sundal Collier, which may cover companies either in accordance with legal requirements designed to promote the independence of investment research ("independent research") or as commissioned research. Commissioned research is paid for by the subject company. As such, commissioned research is deemed to constitute an acceptable minor non-monetary benefit (i.e., not investment research) as defined in MiFID II.

### **Analyst valuation methods**

ABG Sundal Collier analysts may publish valuation ranges for stocks covered under Company Sponsored Research. These valuation ranges rely on various valuation methods. One of the most frequently used methods is the valuation of a company by calculation of that company's discounted cash flow (DCF). Another valuation method is the analysis of a company's return on capital employed relative to its cost of capital. Finally, the analysts may analyse various valuation multiples (e.g. the P/E multiples and the EV/EBITDA multiples) relative to global industry peers. In special cases, particularly for property companies and investment companies, the ratio of price to net asset value is considered. Valuation ranges may be changed when earnings and cash flow forecasts are changed. They may also be changed when the underlying value of a company's assets changes (in the cases of investment companies, property companies or insurance companies) or when factors impacting the required rate of return change.

#### **Expected updates**

ABGSC has no fixed schedule for updating its research reports. Unless expressly stated otherwise, ABGSC expects (but does not undertake) to issue updates when considered necessary by the research department, for example following the publication of new figures or forecasts by a company or in the event of any material news on a company or its industry.

### **Important Company Specific Disclosure**

The following disclosures relate to the relationship between ABG Sundal Collier and its affiliates and the companies covered by ABG Sundal Collier referred to in this research report.

Unless disclosed in this section, ABG Sundal Collier has no required regulatory disclosures to make in relation to an ownership position for the analyst(s) and members of the analyst's household, ownership by ABG Sundal Collier, ownership in ABG Sundal Collier by the company(ies) to whom the report(s) refer(s) to, market making, managed or co-managed public offerings, compensation for provision of certain services, directorship of the analyst, or a member of the analyst's household, or in relation to any contractual obligations to the issuance of this research report.

ABG Sundal Collier has undertaken a contractual obligation to issue this report and receives predetermined compensation from the company covered in this report.

ABG Sundal Collier is not aware of any other actual, material conflicts of interest of the analyst or ABG Sundal Collier of which the analyst knows or has reason to know at the time of the publication of this report.

Production of report: 10/13/2025 08:10.

All prices are as of market close on 10 October, 2025 unless otherwise noted.

#### **Disclaimer**

This report has been prepared by ABG Sundal Collier ASA, ABG Sundal Collier Denmark, filial af ABG Sundal Collier ASA, Norge, ABG Sundal Collier AB and/or ABG Sundal Collier Limited and any of their directors, officers, representatives and employees (hereinafter collectively referred to as "ABG Sundal Collier"). This report is not a product of any other affiliated or associated companies of any of the above entities.

This report is provided solely for the information and use of professional investors, who are expected to make their own investment decisions without undue reliance on this report. The information contained herein does not apply to, and should not be relied upon by, retail clients. This report is for distribution only under such circumstances as may be permitted by applicable law. Research reports prepared by ABG Sundal Collier are for information purposes only. The recommendation(s) in this report is (are) has/ have no regard to specific investment objectives and the financial situation or needs of any specific recipient. ABG Sundal Collier and/or its affiliates accepts no liability whatsoever for any losses arising from any use of this report or its contents. This report is not to be used or considered as an offer to sell, or a solicitation of an offer to buy. The information herein has been obtained from, and any opinions herein are based upon, sources believed reliable, but ABG Sundal Collier and/or its affiliates make no representation as to its accuracy or completeness and it should not be relied upon as such. All opinions and estimates herein

#### Prevas

reflect the judgment of ABG Sundal Collier on the date of this report and are subject to change without notice. Past performance is not indicative of future results.

The compensation of our research analysts is determined exclusively by research management and senior management, but not including investment banking management. Compensation is not based on specific investment banking revenues, however, it is determined from the profitability of the ABG Sundal Collier group, which includes earnings from investment banking operations and other business. Investors should assume that ABG Sundal Collier ASA, ABG Sundal Collier Denmark, filial af ABG Sundal Collier ASA, Norge and/or ABG Sundal Collier AB is seeking or will seek investment banking or other business relationships with the companies in this report.

The research analyst(s) responsible for the preparation of this report may interact with trading desk and sales personnel and other departments for the purpose of gathering, synthesizing and interpreting market information. From time to time, ABG Sundal Collier and/or its affiliates and any shareholders, directors, officers, or employees thereof may (I) have a position in, or otherwise be interested in, any securities directly or indirectly connected to the subject of this report, or (II) perform investment banking or other services for, or solicit investment banking or other services from, a company mentioned in this report. ABG Sundal Collier and/or its affiliates rely on information barriers to control the flow of information contained in one or more areas of ABG Sundal Collier, into other areas, units, groups or affiliates of ABG Sundal Collier.

Norway: ABG Sundal Collier ASA is regulated by the Financial Supervisory Authority of Norway (Finanstilsynet)

Denmark: ABG Sundal Collier Denmark, filial af ABG Sundal Collier ASA, Norge, is regulated by the Financial Supervisory Authority of Norway (Finanstilsynet) and the Danish Financial Supervisory Authority (Finanstilsynet)

Sweden: ABG Sundal Collier AB is regulated by the Swedish Financial Supervisory Authority (Finansinspektionen)

UK: This report is a communication made, or approved for communication in the UK, by ABG Sundal Collier Limited, authorised and regulated by the Financial Conduct Authority in the conduct of its business.

US: This report is being distributed in the United States (U.S.) in accordance with FINRA Rule 1220 by ABG Sundal Collier Inc., an SEC registered broker-dealer and a FINRA/SIPC member which accepts responsibility for its content and its compliance with FINRA Rule 2241. Research reports distributed in the U.S. are intended solely for "major U.S. institutional investors," and "U.S. institutional investors" as defined under Rule 15a-6 of the Securities Exchange Act of 1934 and any related interpretive guidance and no-action letters issued by the Staff of the U.S. Securities and Exchange Commission ("SEC") collectively ("SEC Rule 15a-6"). Each major U.S. institutional investor and U.S. institutional investor that receives a copy of this research report, by its acceptance of such report, represents that it agrees that it will not distribute this research report to any other person. This communication is only intended for major U.S. institutional investors and U.S. institutional investors. Any person which is not a major U.S. institutional investor, or a U.S. institutional investor as covered by SEC Rule 15a-6 must not rely on this communication. The delivery of this research report to any person in the U.S. is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein. Any major U.S. institutional investor or U.S. institutional investor receiving this report which wishes to effect transactions in any securities referred to herein should contact ABG Sundal Collier Inc., not its affiliates. Further information on the securities referred to herein may be obtained from ABG Sundal Collier Inc., on request.

Singapore: This report is distributed in Singapore by ABG Sundal Collier Pte. Ltd, which is not licensed under the Financial Advisors Act (Chapter 110 of Singapore). In Singapore, this report may only be distributed to institutional investors as defined in Section 4A(1)(c) of the Securities and Futures Act (Chapter 289 of Singapore) ("SFA"), and should not be circulated to any other person in Singapore.

Canada: This report is being distributed by ABG Sundal Collier ASA in Canada pursuant to section 8.25 of National Instrument 31-103 or an equivalent provision and has not been tailored to the needs of any specific investor in Canada. The information contained in this report is not, and under no circumstances is to be construed as, a prospectus, an advertisement, a public offering or an offer to sell the securities described herein, in Canada or any province or territory thereof. No securities commission or similar regulatory authority in Canada has reviewed or considered this report, the information contained herein or the merits of the securities described herein and any representation to the contrary is an offence. Under no circumstances is this report to be construed as an offer to sell such securities or as a solicitation of an offer to buy such securities in any jurisdiction of Canada. Any offer or sale of the securities described herein in Canada may only be made in accordance with applicable securities laws and only by a dealer properly registered under such securities laws, or alternatively, pursuant to an applicable dealer registration exemption, in the Canadian jurisdiction in which such offer or sale is made.

This report may not be reproduced, distributed, or published by any recipient for any purpose whatsoever without the prior written express permission of ABG Sundal Collier.

Additional information available upon request. If reference is made in this report to other companies and ABG Sundal Collier provides research coverage for those companies, details regarding disclosures may be found on our website www.abgsc.com.

© Copyright 2025 ABG Sundal Collier ASA

### Norway

Ruseløkkveien 26, 8th floor 0251 Oslo Norway Tel: +47 22 01 60 00

Fax: +47 22 01 60 60

#### Denmark

Forbindelsesvej 12, 2100 Copenhagen Denmark Tel: +45 35 46 61 00

Fax: +45 35 46 61 10

#### Sweden

Regeringsgatan 25, 8th floor 111 53 Stockholm Sweden

Tel: +46 8 566 286 00 Fax: +46 8 566 286 01

#### United Kingdom

10 Paternoster Row, 5th floor London EC4M 7EJ

Tel: +44 20 7905 5600 Fax: +44 20 7905 5601

#### USA

140 Broadway, Suite 4604 New York, NY 10005 USA Tel. +1 212 605 3800 Fax. +1 212 605 3801

Singapore 10 Collyer Quay Ocean Financial Center #40-07, Singapore 049315 Tel +65 6808 6082

#### Germany

Schillerstrasse 2, 5. OG 60313 Frankfurt Germany Tel +49 69 96 86 96 0 Fax +49 69 96 86 96 99

#### Switzerland

ABG Sundal Collier AG Representative Office Schwanenplatz 4 6004 Lucerne Switzerland Tel +41 79 502 33 39